Condition category
Cancer
Date applied
01/07/2001
Date assigned
01/07/2001
Last edited
01/02/2012
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr - -

ORCID ID

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

HD1-82

Study information

Scientific title

Acronym

Study hypothesis

Not provided at time of registration

Ethics approval

Not provided at time of registration

Study design

Non randomised trial

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Trial setting

Not specified

Trial type

Not Specified

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Lymphoma (Hodgkin's)

Intervention

This is a non randomised study, patients are grouped according to site and stage of disease:

1. Group A: Patients with pathological stage Ia (neck), IIa (neck) and Ia (axilla) are assigned to local field radiotherapy. Patients with neck disease receive 30 Gy midline in sixteen fractions over 3 weeks followed by an additional 5 Gy to the site of palpable disease. Patients with axillary disease receive 35 Gy midline in sixteen fractions over 3 weeks.

2. Group B: Patients with pathological stage Ia (supraclavicular), IIa (all sites except neck) are assigned to mantle radiotherapy. Patients receive a dose of 35 Gy mid line in twenty fractions over 4 weeks followed by an additional 6 Gy to the anterior mediastinum.

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/01/1998

Overall trial end date

31/12/2001

Reason abandoned

Eligibility

Participant inclusion criteria

1. Pathological stage Ia and IIa (upper) Hodgkin's disease
2. Aged 15 to 65 years

Participant type

Patient

Age group

Adult

Gender

Not Specified

Target number of participants

Not provided at time of registration

Participant exclusion criteria

Patients with mediastinal disease will not in general be eligible for local radiotherapy alone

Recruitment start date

01/01/1998

Recruitment end date

31/12/2001

Locations

Countries of recruitment

United Kingdom

Trial participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

Funders

Funder type

Charity

Funder name

Cancer Research UK

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/15714929

Publication citations

  1. Results

    Hoskin PJ, Smith P, Maughan TS, Gilson D, Vernon C, Syndikus I, Linch DC, , Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma., Clin Oncol (R Coll Radiol), 2005, 17, 1, 47-53.

Additional files

Editorial Notes